alpha synuclein function
α突触核蛋白功能
基本信息
- 批准号:6754262
- 负责人:
- 金额:$ 34.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-12-01 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:G protein coupled receptor kinaseParkinson&aposs diseaseadeno associated virus groupalpha synucleinbehavior testcorpus striatumdopaminegene delivery systemgene expressiongene therapylaboratory ratlevodopamass spectrometryneural degenerationoxidative stressphospholipase Dprotein protein interactionsubstantia nigrasuperoxide dismutasetransfection /expression vectortyrosine 3 monooxygenase
项目摘要
Recent data from our lab and others have demonstrated that targeted alpha-synuclein overexpression in the substantia nigra pars compacta leads to Parkinson-like neurodegeneration. Yet, the function of alpha synuclein is still unknown. The present proposal attempts to define the function of alpha synuclein in both normal brain function and in the pathogenesis of Parkinson disease (PD). Alpha synuclein is likely to be part of a multiprotein complex, and understanding
the interaction between alpha synuclein and its protein binding partners should help in understanding the mechanism underlying pathogenesis in PD, as well as its function in the normal brain. It might also help explain the selective vulnerability of certain neuronal populations to alpha synuclein. We propose to use recombinant Adeno-Associated Virus (rAAV) as a gene delivery vector to generate regionally specific somatic transgenics of the nigrostriatal tract. The
following 3 aims are proposed. The first aim is to examine the effect of down regulating or overexpressing genes that are known to interact with alpha synuclein. Phospholipase D2 (PLD2) and/or G coupled Receptor protein Kinase 2 (GRK2) will be overexpressed or knocked down in combination with alpha-synuclein to determine whether the known interactions between these proteins and alpha synuclein are involved in the pathogenesis of PD. We will follow the
progression of neurodegeneration caused by these combinations by looking at the number of TH- positive neurons and behavioral deficits. Aim 2 is to identify additional proteins that interact directly with alpha synuclein. Tagged rat and human alpha synuclein will be used as a bait to affinity-immunoprecipitate a synuclein-protein complexes in vivo in the dopaminergic MN9D cell line. The affinity purified complexes will be analyzed by mass spectrometry methods and
antibody to known interaction partners to identify the multiprotein interactions for alpha synuclein. Aim 3 is to determine whether the toxicity of dopamine related oxidative stress is a factor in the selective vulnerability of certain dopaminergic neurons to Parkinson-like neurodegeneration induced by alpha synuclein. AAV will be used to deliver the alpha synuclein gene alone, or in combination with genes that increase or decrease oxidative stress in substantia nigra. These include the tyrosine hydroxylase (TH) and GTP cyclohydrolase genes to increase nigrostriatal dopamine production by overexpression of the precursor L-dopa, and SOD1 and catalase to reduce oxidative stress. As in aim 1 we will follow the progression of neurodegeneration caused by these combinations.
来自我们实验室和其他实验室的最新数据表明,在黑质致密部靶向α-突触核蛋白的过度表达会导致帕金森样神经变性。然而,阿尔法突触核蛋白的功能仍不清楚。本提案试图确定α-突触核蛋白在正常脑功能和帕金森病(PD)发病机制中的作用。α突触核蛋白很可能是多蛋白复合体的一部分,并理解
α突触核蛋白与其蛋白结合伙伴之间的相互作用有助于理解帕金森病的发病机制,以及它在正常大脑中的功能。这也可能有助于解释某些神经元群体对α-突触核蛋白的选择性易感性。我们建议使用重组腺相关病毒(RAAV)作为基因传递载体来产生黑质纹状体束的区域性特异性体细胞转基因。这个
提出了以下三个目标。第一个目标是研究下调或过度表达已知与α-突触核蛋白相互作用的基因的效果。磷脂酶D2(PLD2)和/或G偶联受体蛋白激酶2(GRK2)将被过表达或与α-突触核蛋白联合下调,以确定这些蛋白与α-突触核蛋白之间的已知相互作用是否参与了PD的发病。我们将遵循
通过观察TH阳性神经元的数量和行为缺陷来研究由这些组合引起的神经退行性变的进展。目标2是识别更多与α突触核蛋白直接相互作用的蛋白质。标记的大鼠和人α突触核蛋白将作为诱饵,在体内亲和免疫沉淀多巴胺能MN9D细胞系中的突触核蛋白-蛋白质复合体。亲和纯化的络合物将通过质谱学方法和
针对已知相互作用伙伴的抗体,以识别α突触核蛋白的多蛋白相互作用。目的3确定多巴胺相关氧化应激的毒性是否是某些多巴胺能神经元对α-突触核蛋白诱导的帕金森样神经变性选择性易感性的一个因素。AAV将被用来单独传递α突触核蛋白基因,或者与增加或减少黑质氧化应激的基因结合使用。这些基因包括酪氨酸羟化酶(TH)和GTP环水解酶基因,通过过度表达前体L-多巴来增加黑质纹状体多巴胺的产生,以及SOD1和过氧化氢酶来减少氧化应激。正如在目标1中一样,我们将跟踪这些组合引起的神经退化的进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS MUZYCZKA其他文献
NICHOLAS MUZYCZKA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS MUZYCZKA', 18)}}的其他基金
Identifying and testing new targets for Parkinson Disease gene therapy
识别和测试帕金森病基因治疗的新靶点
- 批准号:
8521403 - 财政年份:2010
- 资助金额:
$ 34.98万 - 项目类别:
Identifying and testing new targets for Parkinson Disease gene therapy
识别和测试帕金森病基因治疗的新靶点
- 批准号:
8151115 - 财政年份:2010
- 资助金额:
$ 34.98万 - 项目类别:
Identifying and testing new targets for Parkinson Disease gene therapy
识别和测试帕金森病基因治疗的新靶点
- 批准号:
8311777 - 财政年份:2010
- 资助金额:
$ 34.98万 - 项目类别:
Identifying and testing new targets for Parkinson Disease gene therapy
识别和测试帕金森病基因治疗的新靶点
- 批准号:
8704739 - 财政年份:2010
- 资助金额:
$ 34.98万 - 项目类别:
Identifying and testing new targets for Parkinson Disease gene therapy
识别和测试帕金森病基因治疗的新靶点
- 批准号:
8040428 - 财政年份:2010
- 资助金额:
$ 34.98万 - 项目类别:
AAV capsid assembly, viral entry, and viral tropism
AAV 衣壳组装、病毒进入和病毒向性
- 批准号:
7115888 - 财政年份:2005
- 资助金额:
$ 34.98万 - 项目类别: